A Phase 2/3, two-part, open-label dose escalation, age de-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to <12 years of age.